Latest Period
Q1 2026
Security Snapshot
GYRE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (GYRE) Institutional Ownership
CUSIP: 403783103
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
55
Shares (Excl. Options)
3,407,283
Price
$6.97
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- GYRE on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 3,407,283
- Total 13F value
- $23,750,622
- Portfolio coverage rank
- 0%
- Share change
- +62,544
- Value change
- +$433,390
- Number of holders
- 55
- Shares outstanding
- 124,924,768
- SEC-reported price per share
- $5.74
- Insider filing price
- $5.74
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- GYRE - GYRE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share is tracked under CUSIP 403783103.
- 55 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 42 to 55 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $23,613,928 to $23,750,622.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 55 institutions filings for Q1 2026.
Security key
403783103
Latest holder period
Q1 2026
13F holders
55
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
GYRE full holder history
GYRE THERAPEUTICS, INC. SEC filings
GYRE THERAPEUTICS, INC. company facts
GYRE THERAPEUTICS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 403783103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
GYRE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GNI Group Ltd. | 69% | $637,927,081 | 86,323,015 | GNI Group Ltd. | 04 May 2026 | |||
| Luo Ying | 8.6% | $75,462,150 | 10,211,387 | Ying Luo | 04 May 2026 | |||
| Ma Songjiang | 6.3% | $54,258,348 | 7,342,131 | Songjiang Ma | 04 May 2026 |
As of 31 Mar 2026, 55 institutional investors reported holding 3,407,283 shares of GYRE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (GYRE). This represents 2.7% of the company’s total 124,924,768 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
10
Latest
Q1 2026
Rows shown
1-10 of 10
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 3,407,283 | $23,750,622 | +$433,390 | $6.97 | 55 |
| 2025 Q4 | 3,344,625 | $23,613,928 | +$1,729,612 | $7.06 | 42 |
| 2025 Q3 | 3,095,667 | $23,092,842 | -$2,342,158 | $7.46 | 46 |
| 2025 Q2 | 3,409,744 | $25,061,360 | +$5,853,520 | $7.35 | 46 |
| 2025 Q1 | 2,609,308 | $20,143,986 | +$6,336,492 | $7.72 | 43 |
| 2024 Q4 | 1,787,221 | $21,627,571 | +$923,657 | $12.10 | 38 |
| 2024 Q3 | 1,610,238 | $20,192,564 | +$4,240,829 | $12.54 | 34 |
| 2024 Q2 | 1,257,751 | $15,005,952 | +$4,350,610 | $11.93 | 29 |
| 2024 Q1 | 816,435 | $14,271,940 | +$3,343,587 | $17.48 | 19 |
| 2023 Q4 | 606,775 | $15,589,189 | +$15,582,189 | $25.69 | 15 |